About Quiver Bioscience
Quiver Bioscience is a biotechnology company that looks for drug targets and drug candidates for brain disorders. It also builds its own pipeline of medicines. Its platform grows patient-derived stem-cell neurons, records their activity with all-optical electrophysiology, and runs AI models on the data. It works with drug companies and patient groups on discovery programs.
Quiver Bioscience works from 150 Cambridge Park Drive in Cambridge, Massachusetts. Graham Dempsey, a co-founder, is chief executive officer, and Dave Liederbach is president. Its dataset covers over 1.5 billion action potentials from over 30 million neurons. Its lead asset is an antisense drug candidate aimed at the pain target Nav1.7. Partners include Angelini Pharma, on genetic epilepsies, and QurAlis, on Fragile X syndrome.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Oct 21, 2026 | $3,005,000target not set | 4 | $751K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Quiver Bioscience
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 13, 2026 | Strategic investment | Undisclosed | Porta family office (Argentina) (lead) | Quiver Bioscience press release ↗ |
Why Investors Backed Quiver Bioscience
Quiver Bioscience builds a platform that records how human neurons behave and uses AI to find drugs for brain disorders. It also develops its own antisense medicines for chronic pain and rare neurological conditions. It has a research and licensing deal with Angelini Pharma and a family investment from Argentina.
The problem it targets
Quiver’s view is that neurological drug development continues to see the lowest success rates. It traces most failures to weak targets, unexpected toxicities, and poor matching of patients to drugs. In its view, the cause is a long lack of scalable human models, reliable neural measurements, and computing power.
What the product does
The platform has three parts. Models are patient-derived stem-cell neurons, plus ex vivo tissue slices used to probe 3D circuits. Signals are all-optical electrophysiology readings of single-neuron activity. Insights are AI models that mine the data to define disease traits, judge drug efficacy, match drugs to targets, and steer clear of unwanted toxicity. Quiver calls the integrated platform its Genomic Positioning System. The dataset covers over 1.5 billion action potentials, over 30 million neurons, 18,000 gene perturbations, and 3,500 drug fingerprints.
Progress so far
Quiver runs wholly owned antisense programs against Nav1.7 and Nav1.8 for chronic pain. Others target UBE3A for Dup15q syndrome and STXBP1 and SYNGAP1 for epileptic encephalopathies. In February 2026, it signed a multi-year research and licensing deal with Angelini Pharma on genetic epilepsies, with milestone payments of up to $120 million. It also has a Fragile X collaboration with QurAlis and two undisclosed pharma partners signed in Q4 2025. In May 2026, it won an NIH HEAL Initiative award for its Nav1.7 therapy.
Who backs it
In April 2026, the Porta family office in Argentina made a targeted investment in the UBE3A program for Dup15q syndrome. The money funds safety studies toward a final development candidate, planned for the second half of 2026. José A. Porta, president of Porta Hnos S.A., described the investment as a deeply personal commitment as the father of a daughter with the condition. Quiver has also won a Phase II NIH grant of $2.15 million over three years. Grants from the Dup15q Alliance, the FRAXA Research Foundation, and the KCNT1 Epilepsy Foundation support its programs.
How the market is moving
Quiver’s July 2025 release describes an FDA push toward replacing preclinical animal safety studies with human cell systems and AI models. Quiver argues that animal studies do not scale and can be costly and slow. It also says antisense drugs are increasingly being developed for neurological conditions.
We wrote this summary from public statements by Quiver Bioscience and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Quiver Bioscience's Form D filed Oct 21, 2026.
